May 2010
iRhythm Enters Into Partnership with St. Jude Medical
iRhythm announced a partnership with St. Jude Medical. iRhythm also announced closure of a $10 million private equity round of financing lead by St. Jude Medical. Existing iRhythm investors Mohr Davidow Ventures and Synergy Life Science Partners also participated in the financing round.
July 2009
iRhythm’s Proprietary Analysis System Receives FDA Clearance
The Zio™ ECG Utilization Service (ZEUS) system is a comprehensive system that processes and analyzes received ECG data captured by long-duration, single-lead, continuous recording diagnostic devices, such as the Zio™ Patch and Zio™ Continuous Card. The ZEUS system uses beat-by-beat QRS detection and a sophisticated rhythm analysis algorithm to detect up to ten categories of rhythms. ZEUS runs on a cloud-computing platform and can be used to analyze up to 14 days of ECG data more rapidly and accurately than traditional systems. The data processed by the ZEUS algorithm is reviewed by a Certified Cardiographic Technician (CCT) to help ensure high accuracy and quality.
May 2009
iRhythm’s Third Product Receives FDA Clearance
The Zio™ Patch is a prescription-only, single-use, continuously recording ECG monitor that constantly records the heart’s electrical activity. The Zio™ Patch can be worn for up to 14 days and is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as pre-syncope, syncope, palpitations, shortness of breath, dizziness, lightheadedness, fatigue or anxiety.
April 2009
iRhythm Receives Additional Funding
iRhythm closes funding from existing investors.
December 2008
iRhythm Acquires the Assets of iCardia Healthcare Corporation
iRhythm acquires iCardia’s Single Use Patient Event Recorder (SUPER) and proprietary application software for the diagnosis of cardiac arrhythmias. As a part of the acquisition, iRhythm also acquired iCardia’s monitoring center, now known as the iRhythm National Clinical Center (iNCC). iNCC is an Independent Diagnostic Testing Facility (IDTF) dedicated to providing world-class clinical monitoring and customer service. Led by a management team with more than 40 years of experience in ambulatory cardiac rhythm monitoring, the iNCC provides monitoring services performed by experienced Certified Cardiographic Technicians (CCT). The iNCC also manages physician and patient enrollments, clinical reports, inventory control and reimbursement consultations. The iNCC operates 24 hours a day, 7 days a week and offers language interpretation for more than 170 languages.
June 2008
iRhythm’s First Products Receive FDA Clearance
Zio™ Event Card
The Zio™ Event Card is a prescription-only, single-use, looping ECG monitor that records the heart’s rhythm when the patient pushes a button upon feeling a symptom. The Zio™ Event Card can be worn for up to 30 days and is indicated for use on patients who experience transient symptoms such as syncope, palpitations, shortness of breath, or dizziness.
Zio™ Continuous Card
The Zio™ Continuous Card is a prescription-only, single-use, continuously recording ECG monitor that constantly records the heart’s electrical activity. The Zio™ Continuous Card can be worn for up to 7 days and is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as pre-syncope, syncope, palpitations, shortness of breath, dizziness, lightheadedness, fatigue or anxiety.
May 2008
iRhythm Receives Additional Funding
iRhythm closes funding from existing investors and is joined by the UNC Kenan-Flagler Private Equity Fund.
January 2007
iRhythm Receives Initial Funding
William F. Willis, a veteran of the cardiac monitoring industry, joins as President and CEO and iRhythm closes funding from venture investors Mohr Davidow Ventures and Synergy Life Science Partners.
September 2006
iRhythm Technologies is Founded
As a fellow in Stanford University’s Biodesign Program, Uday N. Kumar, MD, iRhythm’s Founder and Chief Medical Officer and a cardiac electrophysiologist by training, worked with two engineers and a business school graduate to identify key unmet clinical needs in the field of cardiac electrophysiology. They found that many patients suffering from arrhythmias were not being diagnosed due to significant limitations in currently available devices and to complexities of the processes required to initiate and monitor for arrhythmias. Based on these insights, they came up with the concept that is at the foundation of iRhythm.